Taken together, the above phase 3 clinical trials provide evidence that toripalimab in combination with chemotherapy conferred better OS than chemotherapy alone in first-line treatment of patients with advanced and/or metastatic NPC, NSCLC or ESCC irrespective of PD-L1 expression. The gene discussed is CD274; the disease is nasopharyngeal carcinoma.